We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes

News   Aug 13, 2018 | Original story from Cleveland Clinic

 
New Class of Drugs May Reduce Cardiovascular Risk by Targeting Gut Microbes
 
 
 

RELATED ARTICLES

New Libido Drug Vyleesi Approved to Treat Hypoactive Sexual Desire in Women

News

The U.S. Food and Drug Administration today approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

READ MORE

Pathogen Engineered to Self-Destruct Underlies Cancer Vaccine Platform

News

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors.

READ MORE

Clinical Trial Assessing Treatments for Preventing People at High Risk From Developing Multidrug-resistant TB Launches

News

A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE